Key result
Doxorubicin use in elderly patients with diffuse large B-cell lymphoma was associated with a 29% increased risk of congestive heart failure (HR 1.29; 95% CI 1.02-1.62).
Why the study?
Does doxorubicin increase the risk of congestive heart failure in elderly patients with diffuse large B-cell lymphoma?
Population
9,438 patients age ≥ 65 years diagnosed with diffuse large B-cell lymphoma from 1991 to 2002 in the…
Comparison
Doxorubicin-based chemotherapy vs Patients not treated with doxorubicin
Design
Cohort
Follow-up
8 years
Authors
Loading...
May warrant closer cardiac monitoring in elderly DLBCL patients on doxorubicin; leaves open optimal prevention strategies pending prospective confirmation.
Cohort (n=9,438)
Yes
Does doxorubicin increase the risk of congestive heart failure in elderly patients with diffuse large B-cell lymphoma?
Effect estimate: HR 1.29 (95% CI 1.02-1.62)
Absolute Event Rate: 74% vs 79%
In elderly patients with DLBCL, doxorubicin-based chemotherapy significantly increases the risk of congestive heart failure, an effect that is exacerbated by concurrent hypertension.
Hershman et al. (2008) conducted a cohort in diffuse large B-cell lymphoma (DLBCL) (n=9,438). doxorubicin-based chemotherapy vs. no doxorubicin treatment was evaluated on congestive heart failure (CHF-free survival rate) (HR 1.29, 95% CI 1.02-1.62). Doxorubicin use in elderly patients with diffuse large B-cell lymphoma was associated with a 29% increased risk of congestive heart failure (HR 1.29; 95% CI 1.02-1.62).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: